<DOC>
	<DOC>NCT00037596</DOC>
	<brief_summary>The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.</brief_summary>
	<brief_title>Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Morphologic diagnosis of AML from bone marrow aspirate and biopsy Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33+, based on local laboratory criteria Age 18 years or older for relapsed or refractory patients for Phase I of this study Patients with de novo AML of the M3 subtype AML following an antecedent hematologic disorder (myelodysplasia or myeloproliferation) of &gt; 2 months duration AML secondary to exposure to chemotherapy or radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>